Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
about
Growth Differentiation Factor-15 (GDF-15) Level and Relation to Clinical Manifestations in Egyptian Systemic Sclerosis patients: Preliminary Data.Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
P2860
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Treatment of Systemic Sclerosi ...... isting and Emerging Therapies.
@en
type
label
Treatment of Systemic Sclerosi ...... isting and Emerging Therapies.
@en
prefLabel
Treatment of Systemic Sclerosi ...... isting and Emerging Therapies.
@en
P2860
P1476
Treatment of Systemic Sclerosi ...... isting and Emerging Therapies.
@en
P2093
Donald P Tashkin
Elizabeth R Volkmann
P2860
P304
P356
10.1513/ANNALSATS.201606-426FR
P577
2016-08-25T00:00:00Z